The NT Council recommends that the county council uses Ocrevus▼(ocrelizumab) fIslandThe primary advanced MS treatment. In MS forestry, the NT Council recommends county councils to use the most cost effective treatment. TLV assesses Ocrevus as cost-effective or cost savings compared to other approved options.
The NT Council recommends the county council that Ocrevus ▼ (ocrelizumab) may be introduced as a treatment option for advanced MS and forest MS.
- In the primary progressive MS, Ocrevus can be used as a treatment option for a defined patient group *.
- In MS forestry, county councils are recommended to use MS most cost-effective treatment among the alternatives available.
The Dental and Pharmaceutical Agency assesses cost-effective Ocrevus in comparison to a number of other relevant options in MS forestry. Ocrevus is therefore regulated and health is evaluated economically and is now available as an alternative to treating MS MS patients.
"We are very pleased with this recommendation from the HC Council. Ocrevus has proved convincing results in global studies in MS forest and advanced primary MS. Ocrevus is approved in 70 countries and over 70,000 patients have already receiving treatment, says Margareta Olsson Birgersson, Medical Director of Roche, Sweden.
– It is positive that we now have another alternative for MS forest, and for the first time we have an approved treatment for primary advanced MS. For patients, it is very valuable with new options that can slow down an illness course effectively and be a long time treatment, said Jan Lycke, Professor of Neurology, Gothenburg University, and Senior Lecturer at Sahlgrenska University Hospital.
* Age ≤ 55 years, length of illness ≤ 15 years, EDSS ≤ 6.5, signs of inflammatory infirmity due to the presence of recent loading load lesions (about 3 months) and MR performed.
Ocrevus is a targeted human antibody drug designed to specifically target positive B2020 cells B. Ocrevus has planned to be particularly suitable for long-term MS treatment and is & Demonstrate a low degree of drug adverse formation. Ocrevus is put into infusion twice a year.
CD20 is a protein that is found on the body's B cell surface, which has a key role in the inflammation that occurs in multiple sclerosis and leads to harm to myelin and axons. These injuries lead to disability in most people with MS. Clinical studies show that Ocrevus reduces the number of positive CD20 B cells. However, Ocrevus does not affect cell cells or plasma cells, which means that the important functions of the immune system are kept.
For more information
Lotta Luciani, Communications Manager, Roche AB, 073-334 23 13, email@example.com
1.NT Advice: https://janusinfo.se/nationalordnatforfor.4.7c82b0fc1638b8db71b12b21.html
2ndDentistry and Drug Rehabilitation: https://www.tlv.se/download/18.15b37133165bb795253817be/1536757705126/bes180903_underlag_ocrevus.pdf
▼This medication is subject to better monitoring. This will allow you to identify new security information quickly. Healthcare workers are asked to report any suspected adverse reaction. The report should be made to the Swedish Medicines Agency www.lakemedelsverket.se or directly to Roche at firstname.lastname@example.org or by phone 08 – 726 12 00.
Roche is a global pioneer in pharmacies and diagnostics that focuses on bringing science on to improve people's lives. The combined strength of drugs and indoor diagnostics has made Roche a leader in tailored treatment – a strategy that aims to give all patients the right treatment in the best possible way.
Roche is the world's largest biotechnology company with differentiated drugs in oncology, immunology, infectious diseases, ophthalmology and disorders and nervous system. Roche is also a global leader in in vitro diagnostics and a diagnosis of tissue based cancer and has a wide range of diabetes control products. The company was established in 1896, and Roche has been looking for better ways of preventing, diagnosing and treating diseases and contributing to society. The company also aims to improve patient access to medical innovations by working with all stakeholders. Thirty drugs developed by Roche have been included in the World Health Organization's Essential Medicines Model List (WHO), among these life-saving antibiotics, malaria drugs and cancer drugs. For 10 years, Roche has been recognized as a leader in sustainability, within the Pharmaceutical Industry, Biotechnology and Life Sciences, Dow Jones Sustainability Index.
Rochek, headquartered in Basel, Switzerland, operates in over 100 countries and in 2017 had more than 94,000 employees worldwide. In 2017, Roche invested 10.4 billion Swiss francs in Switzerland's 53.3 billion French franchise research and development. Genentech American is a fully owned member of the Roche Group. Roche has a majority in Japanese Pharmaceutical Chugai. For more information, visit www.roche.com. In Sweden there are two subsidiary companies; Roche Diagnostics Scandinavia AB with 95 employees and Roche AB, who is marketing and researching pharmaceuticals with 116 employees in 2017. For more information, visit www.roche.se.